人絲氨酸蛋白酶抑制劑|Human Vaspin
產(chǎn)品名稱: 人絲氨酸蛋白酶抑制劑|Human Vaspin
產(chǎn)品型號: C02-130-11-100ug
產(chǎn)品展商: peprotech
產(chǎn)品文檔: 無相關文檔
簡單介紹
人絲氨酸蛋白酶抑制劑|Human Vaspin系列產(chǎn)品主要適用于試驗室或生化科研相關試驗,CANSPEC品質(zhì)提供的人絲氨酸蛋白酶抑制劑|Human Vaspin性能**,中文名稱為人絲氨酸蛋白酶抑制劑|Human Vaspin。產(chǎn)品人絲氨酸蛋白酶抑制劑|Human Vaspin以其優(yōu)良的品質(zhì)滿足您不同科研實驗的多種需求。
人絲氨酸蛋白酶抑制劑|Human Vaspin
的詳細介紹
產(chǎn)品名稱:人絲氨酸蛋白酶抑制劑|Human Vaspin
產(chǎn)品規(guī)格:
C02-130-11-100ug | 人絲氨酸蛋白酶抑制劑|Human Vaspin | 100ug | ¥9,800 |
C02-130-11-1mg | 人絲氨酸蛋白酶抑制劑|Human Vaspin | 1mg | ¥42,000 |
C02-130-11-25ug | 人絲氨酸蛋白酶抑制劑|Human Vaspin | 25ug | ¥1,960 |
C02-130-11-500ug | 人絲氨酸蛋白酶抑制劑|Human Vaspin | 500ug | ¥25,200 |
C02-130-11-5ug | 人絲氨酸蛋白酶抑制劑|Human Vaspin | 5ug | ¥680 |
單 位:瓶
關 鍵 字:人絲氨酸蛋白酶抑制劑|Human Vaspin
CANSPEC品質(zhì)提供的人絲氨酸蛋白酶抑制劑|Human Vaspin性能**,英文名稱人絲氨酸蛋白酶抑制劑|Human Vaspin,簡稱為人絲氨酸蛋白酶抑制劑|Human Vaspin,中文名稱為人絲氨酸蛋白酶抑制劑|Human Vaspin。
產(chǎn)品人絲氨酸蛋白酶抑制劑|Human Vaspin以其優(yōu)良的品質(zhì)滿足您不同實驗的多種需求。并保證每批人絲氨酸蛋白酶抑制劑|Human Vaspin的質(zhì)量和人絲氨酸蛋白酶抑制劑|Human Vaspin品質(zhì)優(yōu)良。
Synonyms : | Visceral adipose tissue-derived serpin |
Description : | Vaspin is a newly described adipocytokine expressed predominantly in visceral white adipose tissues. Structure analysis of Vaspin predicts the presence of three β-sheets, nine α-helices, and one central loop, which are distinctive structural features of Serpin family members. The serpins are irreversible (“suicidal”) serine-protease inhibitors, characterized by having more than 30% sequence homology with α1-antitrypsin and a conserved tertiary structure, which contains an exposed reactive center loop that acts as a pseudo-substrate for the target proteinase. Members of this family play an important role in a number of fundamental biological processes including blood coagulation, fibrinolysis, complement activation, angiogenesis, inflammation, and tumor suppression. In human, the serpins represent approximately 2% of total serum proteins, of which 70% is α1- antitrypsin. Vaspin exhibits 40.2% sequence identity with α-1-antitrypsin. Yet, its protease inhibitory activity is still unknown. Vaspin mRNA expression in visceral fat is positively correlated with BMI and percent of body fat. Administration of Vaspin to obese mice improved glucose tolerance and insulin sensitivity, reflected by normalized blood glucose levels. It also led to the reversal of altered expression of diabetes-relevant adipocytokines including leptin, adiponectin, resistin, and TNF-α. These findings suggest a potential clinical use for Vaspin in ameliorating certain aberrations seen in the diabetic/obesity metabolic syndrome. Recombinant human Vaspin is a 45.2 kDa protein containing 395 amino-acid residues. |
Catalog #: | 130-11 |
Source : | E.coli |
Stability : | The lyophilized protein is stable for at least 2 years from date of receipt at -200C. Reconstituted Vaspin is stable for at least 3 months when stored in working aliquots with a carrier protein at -200C. Avoid repeated freeze/thaw cycles. |
Purity : | Greater than 98% by SDS-PAGE gel and HPLC analyses. |
Endotoxin Level : | Endotoxin level is less than 0.1 ng per μg (1EU/μg). |
Biological Activity : | Data Not Available. |
AA Sequence : | MLKPSFSPRN YKALSEVQGW KQRMAAKELA RQNMDLGFKL LKKLAFYNPG RNIFLSPLSI STAFSMLCLG AQDSTLDEIK QGFNFRKMPE KDLHEGFHYI IHELTQKTQD LKLSIGNTLF IDQRLQPQRK FLEDAKNFYS AETILTNFQN LEMAQKQIND FISQKTHGKI NNLIENIDPG TVMLLANYIF FRARWKHEFD PNVTKEEDFF LEKNSSVKVP MMFRSGIYQV GYDDKLSCTI LEIPYQKNIT AIFILPDEGK LKHLEKGLQV DTFSRWKTLL SRRVVDVSVP RLHMTGTFDL KKTLSYIGVS KIFEEHGDLT KIAPHRSLKV GEAVHKAELK MDERGTEGAA GTGAQTLPME TPLVVKIDKP YLLLIYSEKI PSVLFLGKIV NPIGK |
PubMed Link : | Vaspin |
Country of Origin : | USA |